PulseSight Therapeutics, a French biotech startup, is focusing on non-viral gene therapies for age-related macular degeneration (AMD).

The startup has attracted seed funding from notable investors including Pureos Bioventures, ND Capital, and Korea Investment Partners.

PulseSight Therapeutics is currently in the process of raising Series A funding to propel its gene therapy candidates into clinical trials.

CEO Judith Greciet is at the helm of the company, which holds 90 patents for its technology.

The company's primary program, PST-809, targets wet AMD, and a second program, PST-611, is developed for dry AMD.

Preclinical testing has yielded promising results for PulseSight's non-viral gene therapies, earning support from industry experts.

PulseSight Therapeutics aims to address the unmet needs in ophthalmology and is positioned to significantly impact the field.